The long-acting insulin class, which includes<unk> , do not appear much better than neutral protamine Hagedorn (NPH) insulin, but do have a greater cost, making them, as of 2010, not cost effective for the treatment of type 2 diabetes. In a previous review is was unclear if there is a difference in hypoglycemia, as there was not enough data to determine any differences with respect to long term outcomes, however a more recent Cochrane systematic review did not find clinically significant difference when comparing<unk>  to NHP insulin, insulin detemir or insulin degludec in the management of type I Diabetes in neither adults or children in periods of 6 months or longer. It is not typically the recommended long acting insulin in the United Kingdom. Mixing with other insulins Unlike some other longer-acting insulins,<unk>  must not be diluted or mixed with other insulin or solution in the same syringe. However, this restriction has been questioned.
Insulin glargine
Insulin aspart
Insulin glulisine
Lente insulin
Regular insulin
Insulin detemir
NPH insulin
Insulin lispro